Skip to main content

Table 3 Drug-Related Adverse Events Occurring in ≥ 15% of Patients Who Received Vorinostat Monotherapy in the Vorinostat Clinical Trial Program (Data Cut-Off April 2008)

From: Vorinostat in solid and hematologic malignancies

Adverse Event No. (%) of Patients (N= 341)
  All Grades Grade 3 or 4
Fatigue 211 (61.9) 41 (12.0)
Nausea 190 (55.7) 14 (4.1)
Diarrhea 168 (49.3) 14 (4.1)
Anorexia 164 (48.1) 17 (5.0)
Vomiting 112 (32.8) 5 (1.5)
Blood creatinine increased 88 (25.8) 2 (0.6)
Weight decreased 86 (25.2) 4 (1.2)
Hyperglycemia 79 (23.2) 10 (2.9)
Thrombocytopenia 71 (20.8) 36 (10.6)
Platelet count decreased 65 (19.1) 18 (5.3)
Hemoglobin decreased 60 (17.6) 10 (2.9)
Constipation 60 (17.6) 3 (0.9)
Dysgeusia 59 (17.3) 0 (0.0)